STOCK TITAN
  1. Home
  2. Sec-filings
  3. NBP
  4. [Form 4] NovaBridge Biosciences Insider Trading Activity

NovaBridge Biosciences (NBP) CMO sells shares while exercising RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NovaBridge Biosciences Chief Medical Officer Dennis Phillip Andrew reported a combination of option activity and share sales. He sold 8,494 Ordinary Shares in an open-market sale at $0.66 per share and, the prior day, exercised derivative awards into 10,302 Ordinary Shares represented by American Depositary Shares (ADSs). Following these transactions, he directly held 157,941 Ordinary Shares and 82,422 Restricted Share Units (RSUs), which each represent a right to receive one ADS.

Positive

  • None.

Negative

  • None.
Insider Dennis Phillip Andrew
Role Chief Medical Officer
Sold 8,494 shs ($6K)
Type Security Shares Price Value
Sale Ordinary Shares 8,494 $0.66 $6K
Exercise Restricted Share Units 10,302 $0.00 --
Exercise Ordinary Shares 23,695 $0.00 --
Holdings After Transaction: Ordinary Shares — 157,941 shares (Direct, null); Restricted Share Units — 82,422 shares (Direct, null)
Footnotes (1)
  1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. Reported securities are represented by 10,302 ADSs. Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. Reported securities are represented by 72,363 ADSs. Reported securities are represented by 3,693 ADSs. Reported sales price represents the converted sales price of the ADSs of $1.51. Reported securities are represented by 68,670 ADSs. Reported securities represent ADSs. On June 17, 2024, the Reporting Person was granted 164,840 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 17th day of each third month.
Ordinary Shares sold 8,494 shares Open-market sale on 2026-06-18
Sale price per Ordinary Share $0.66 per share Converted from ADS sales price
ADS sale price $1.51 per ADS Footnote F6 converted sales price
RSUs exercised 10,302 units Converted into Ordinary Shares on 2026-06-17
Ordinary Shares after transactions 157,941 shares Direct ownership following sale
RSUs remaining 82,422 units Direct RSU holdings after exercise
RSU grant size 164,840 RSUs Granted on 2024-06-17, vesting over four years
American Depositary Shares financial
"The Ordinary Shares may be represented by American Depositary Shares ("ADS")."
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Restricted Share Units financial
"On June 17, 2024, the Reporting Person was granted 164,840 RSUs."
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
RSU financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one ADS."
Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.
open-market sale financial
"transaction_action: "open-market sale" for 8,494 Ordinary Shares."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion" for RSUs into Ordinary Shares."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dennis Phillip Andrew
(Last)(First)(Middle)
C/O NOVABRIDGE BIOSCIENCES
2440 RESEARCH BOULEVARD, SUITE 400
(Street)
ROCKVILLE MARYLAND 20850
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares(1)06/17/2026M23,695(2)A(3)166,435(4)D
Ordinary Shares(1)06/18/2026S8,494(5)D$0.66(6)157,941(7)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Share Units(3)06/17/2026M10,302(8) (9) (9)Ordinary Shares(1)10,302(8)$082,422(8)D
Explanation of Responses:
1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
2. Reported securities are represented by 10,302 ADSs.
3. Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
4. Reported securities are represented by 72,363 ADSs.
5. Reported securities are represented by 3,693 ADSs.
6. Reported sales price represents the converted sales price of the ADSs of $1.51.
7. Reported securities are represented by 68,670 ADSs.
8. Reported securities represent ADSs.
9. On June 17, 2024, the Reporting Person was granted 164,840 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 17th day of each third month.
/s/ Xi-Yong (Sean) Fu as attorney-in-fact06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did NovaBridge Biosciences (NBP) report for its CMO?

NovaBridge Biosciences’ Chief Medical Officer reported an open-market sale and RSU exercises. He sold 8,494 Ordinary Shares at $0.66 per share and exercised derivative awards into 10,302 Ordinary Shares represented by ADSs, while retaining a sizeable equity position afterward.

How many NovaBridge Biosciences (NBP) shares did the CMO sell and at what price?

The CMO sold 8,494 Ordinary Shares of NovaBridge Biosciences at $0.66 per share. A footnote explains this reflects a converted ADS sales price of $1.51, because the company’s Ordinary Shares may also trade as American Depositary Shares in the market.

What derivative or RSU activity did the NovaBridge Biosciences (NBP) CMO report?

He exercised derivative securities described as Restricted Share Units, converting 10,302 RSUs into an equivalent number of Ordinary Shares represented by ADSs. Each RSU corresponds to one ADS, giving him actual share ownership instead of contingent rights once the units vest and convert.

What are the CMO’s NovaBridge Biosciences (NBP) holdings after these transactions?

After the reported transactions, the CMO directly held 157,941 Ordinary Shares and 82,422 Restricted Share Units. These RSUs represent contingent rights to receive ADSs as they vest under the award terms, supplementing his existing Ordinary Share ownership stake in the company.

What RSU grant terms apply to the NovaBridge Biosciences (NBP) CMO?

On June 17, 2024, the CMO was granted 164,840 RSUs. One quarter vests on the first anniversary of the grant date, with the remaining three quarters vesting in equal installments over the subsequent 12 quarters, on the 17th day of every third month.